Hana Biosciences (OTC:HNAB) has announced the data from its Phase 2 rALLy clinical trial for Marqibo®. Marqibo® is for the treatment of second relapse adult acute lymphoblastic leukemia (ALL). Results from the trial demonstrate evidence of single agent, anti-leukemic activity in a relapse, heavily pre-treated, adult population of ALL patients.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
Thirty six percent of the first fifty-six subject demonstrated complete remission, or complete remission. Twenty one percent of the subjects showed complete remission with hematologic recovery. The final data of the sixty five subjects enrolled in the trial will be released in 2010.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
